Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
<Bundle xmlns="http://hl7.org/fhir">
<id value="bundlepackageleaflet-en-832482791de362ad81d3371194ed350b"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Bundle-uv-epi"/>
</meta>
<language value="en"/>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="None"/>
</identifier>
<type value="document"/>
<timestamp value="2023-06-27T10:09:22Z"/>
<entry>
<fullUrl
value="Composition/composition-en-832482791de362ad81d3371194ed350b"/>
<resource>
<Composition>
<id value="composition-en-832482791de362ad81d3371194ed350b"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Composition-uv-epi"/>
</meta>
<language value="en"/>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><a name="Composition_composition-en-832482791de362ad81d3371194ed350b"> </a><p class="res-header-id"><b>Generated Narrative: Composition composition-en-832482791de362ad81d3371194ed350b</b></p><a name="composition-en-832482791de362ad81d3371194ed350b"> </a><a name="hccomposition-en-832482791de362ad81d3371194ed350b"> </a><a name="composition-en-832482791de362ad81d3371194ed350b-en-US"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">Language: en</p><p style="margin-bottom: 0px">Profile: <a href="https://build.fhir.org/ig/HL7/emedicinal-product-info/StructureDefinition-Composition-uv-epi.html">Composition (ePI)</a></p></div><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/21/1604/001 120 actuations</p><p><b>status</b>: Final</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/rmswi/ 100000155538}">Package Leaflet</span></p><p><b>category</b>: <span title="Codes:{http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs R}">Raw</span></p><p><b>date</b>: 2022-02-16 13:28:17+0000</p><p><b>author</b>: <a href="Organization-mah-ema.html">Organization ACME industry</a></p><p><b>title</b>: TEST PURPOSES ONLY - riltrava</p><h3>Attesters</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Mode</b></td><td><b>Time</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://hl7.org/fhir/composition-attestation-mode official}">Official</span></td><td>2022-02-16 13:28:17+0000</td></tr></table></div>
</text>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="EU/1/21/1604/001 120 actuations"/>
</identifier>
<status value="final"/>
<type>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="Package Leaflet"/>
</type>
<category>
<coding>
<system
value="http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs"/>
<code value="R"/>
<display value="Raw"/>
</coding>
</category>
<subject>
<reference
value="MedicinalProductDefinition/mp832482791de362ad81d3371194ed350b"/>
</subject>
<date value="2022-02-16T13:28:17Z"/>
<author>🔗
<reference value="Organization/mah-ema"/>
</author>
<title value="TEST PURPOSES ONLY - riltrava"/>
<attester>
<mode>
<coding>
<system
value="http://hl7.org/fhir/composition-attestation-mode"/>
<code value="official"/>
</coding>
</mode>
<time value="2022-02-16T13:28:17Z"/>
</attester>
<section>
<title value="B. Package Leaflet"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="B. Package Leaflet"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
<emptyReason>
<coding>
<system
value="http://terminology.hl7.org/CodeSystem/list-empty-reason"/>
<code value="unavailable"/>
</coding>
</emptyReason>
<section>
<title value="Package leaflet: Information for the user"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="Package leaflet: Information for the user"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Instructions for use</p></div>
</text>
</section>
<section>
<title value="What is in this leaflet"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="What is in this leaflet"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>What is in this leaflet</p><ol type="1"><li>What Riltrava Aerosphere is and what it is used for</li><li>What you need to know before you use Riltrava Aerosphere</li><li>How to use Riltrava Aerosphere</li><li>Possible side effects</li><li>How to store Riltrava Aerosphere</li><li>Contents of the pack and other information</li></ol></div>
</text>
</section>
<section>
<title value="1. What riltrava is and what it is used for"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="1. What riltrava is and what it is used for"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Riltrava Aerosphere contains three active substances: formoterol fumarate dihydrate, glycopyrronium, and budesonide.</p><p>Formoterol fumarate dihydrate and glycopyrronium belong to a group of medicines called bronchodilators . They work in different ways to prevent tightening of the muscles around the airways, making it easier for air to get in and out of the lungs.</p><p>Budesonide belongs to a group of medicines called corticosteroids . These work by reducing inflammation in your lungs. Riltrava Aerosphere is an inhaler that is used for adults with a lung disease called chronic obstructive pulmonary disease (or COPD ), a long-term disease of the airways in the lungs. Riltrava Aerosphere is used to make breathing easier and improve symptoms of COPD such as shortness of breath, wheezing and cough. Riltrava Aerosphere can also prevent flare-ups (exacerbations) of COPD. Riltrava Aerosphere delivers the active substances into your lungs as you breathe in. If you use this medicine regularly twice a day, it will help to reduce the effects of COPD on your everyday life.</p></div>
</text>
</section>
<section>
<title value="2. What you need to know before you take riltrava"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text
value="2. What you need to know before you take riltrava"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Do not use Riltrava Aerosphere</p><p>if you are allergic to formoterol fumarate dihydrate, glycopyrronium, budesonide or any of the other ingredients of this medicine (listed in section 6). Warnings and precautions Riltrava Aerosphere is used as a long-term maintenance treatment for COPD. Do not use it to treat a sudden attack of breathlessness or wheezing. Immediate breathing difficulties If you get tightness of the chest, coughing, wheezing or breathlessness immediately after using Riltrava Aerosphere, stop using it and tell your doctor straight away (see Serious side effects at the top of Section 4 for more information). If your breathlessness, tightness of the chest, wheezing or coughing is getting worse while using Riltrava Aerosphere, you should continue to use Riltrava Aerosphere but contact your doctor as soon as possible, as you may need additional treatment. Talk to your doctor before using Riltrava Aerosphere if:</p><p>you have high blood pressure or heart problems</p><p>you have diabetes</p><p>you have a lung infection</p><p>you have problems with your thyroid gland</p><p>you have low levels of potassium in your blood</p><p>you have prostate problems or any problems passing urine</p><p>you have an eye problem called angle-closure glaucoma</p><p>you have kidney or liver problems. Talk to your doctor if you think any of these may apply to you. Children and adolescents Riltrava Aerosphere has not been studied in children and adolescents. Do not give this medicine to children or adolescents below the age of 18 years. Other medicines and Riltrava Aerosphere Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. This includes medicines obtained without a prescription, and herbal medicines. This is because Riltrava Aerosphere can affect the way some medicines work. Also some medicines can affect how Riltrava Aerosphere works, or make it more likely that you will have side effects. Tell your doctor or pharmacist if you are taking any of the following:</p><p>medicines called beta-blockers (such as atenolol or propranolol), that may be used for high blood pressure or heart problems, or to treat glaucoma (such as timolol)</p><p>medicines which are used to treat fungal infections such as ketoconazole or itraconazole</p><p>medicines which are used to treat HIV infection such as ritonavir or cobicistat</p><h2 id="medicines-that-lower-the-amount-of-potassium-in-your-blood-such-as">medicines that lower the amount of potassium in your blood, such as:</h2><h2 id="corticosteroids-that-you-take-by-mouth-such-as-prednisolone">corticosteroids that you take by mouth (such as prednisolone),</h2><h2 id="diuretics-medicines-that-increase-urine-production-such-as-furosemide-or-hydrochlorothiazide-which-can-be-used-for-treating-high-blood-pressure">diuretics medicines that increase urine production (such as furosemide or hydrochlorothiazide), which can be used for treating high blood pressure,</h2><p>some medicines used to treat breathing problems (such as theophylline) called methylxanthines ,</p><p>any medicines that work in the same way as Riltrava Aerosphere such as tiotropium, ipratropium, aclidinium, umeclidinium or salmeterol, arformoterol, vilanterol, olodaterol or indacaterol. Do not use Riltrava Aerosphere if you already use these medicines.</p><p>medicines which are used to treat heart rhythm problems such as amiodarone</p><h2 id="medicines-which-can-change-some-electrical-activity-of-the-heart-called-the-qt-interval--such-as-medicines-for">medicines which can change some electrical activity of the heart (called the QT interval ) such as medicines for:</h2><h2 id="depression-such-as-monoamine-oxidase-inhibitors-or-tricyclic-antidepressants">depression (such as monoamine oxidase inhibitors or tricyclic antidepressants),</h2><h2 id="bacterial-infections-such-as-erythromycin-clarithromycin-or-telithromycin">bacterial infections (such as erythromycin, clarithromycin or telithromycin),</h2><p>allergic reactions (anti-histamines). If any of the above applies to you, or if you are not sure, talk to your doctor or pharmacist before using Riltrava Aerosphere. Pregnancy and breast-feeding If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. Do not use Riltrava Aerosphere if you are pregnant unless your doctor tells you that you can. Do not use this medicine if you are breast-feeding unless your doctor tells you that you can. Driving and using machines It is unlikely that this medicine will affect your ability to drive or use machines. However, dizziness is an uncommon side effect which should be taken into account when driving or using machines.</p></div>
</text>
</section>
<section>
<title value="3. How to take riltrava"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="3. How to take riltrava"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Always use this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure. How much to use The recommended dose is two puffs twice a day two puffs in the morning and two puffs in the evening. It is important to use Riltrava Aerosphere every day even if you have no COPD symptoms at the time. Remember: Always rinse your mouth with water after using Riltrava Aerosphere. This is to remove any medicine which is left in the mouth. Spit this water out do not swallow. How to use Riltrava Aerosphere is for inhalation use. Please read the Instructions for Use at the end of this leaflet. If you are not sure how to use Riltrava Aerosphere, talk to your doctor or pharmacist. Using Riltrava Aerosphere with a spacer You may find it difficult breathing in and pressing the inhaler at the same time. If this happens, talk to your doctor or pharmacist. It may help to use a spacer with your inhaler. If you use more Riltrava Aerosphere than you should If you have used more Riltrava Aerosphere than you should, talk to a doctor or pharmacist straight away. You may need medical attention. You may notice that your heart is beating faster than usual, you feel shaky, you have problems with your sight, you have a dry mouth or you have a headache or feel sick (nausea). If you forget to use Riltrava Aerosphere Do not take a double dose to make up for a forgotten dose. Take it as soon as you remember. However, if it is nearly time for your next dose, skip the missed dose. Do not take more than two puffs twice a day on the same day. If you stop using Riltrava Aerosphere This medicine is for long-term use. Use this medicine for as long as your doctor tells you to. It will only be effective as long as you are using it. Do not stop unless your doctor tells you to even if you feel better as your symptoms may get worse. If you want to stop treatment, talk to your doctor first. If you have any further questions on the use of this medicine, talk to your doctor or pharmacist.</p></div>
</text>
</section>
<section>
<title value="4. Possible side effects"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="4. Possible side effects"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Like all medicines, this medicine can cause side effects, although not everybody gets them. The following side effects may happen with this medicine: Serious side effects Uncommon (may affect up to 1 in 100 people) Immediate breathing difficulties:</p><p>if you get breathing difficulties straight after using Riltrava Aerosphere, such as tightness of the chest, coughing, wheezing or feeling breathless, stop using this medicine and tell your doctor straight away. Allergic reactions:</p><p>swelling of your face, particularly around your mouth (swelling of your tongue or throat may make it difficult to swallow)</p><p>rash or hives together with difficulty breathing</p><p>suddenly feeling faint These symptoms may be signs of an allergic reaction which may become serious. Stop using this medicine and call for medical help straight away if you notice the serious side effects above. Other side effects Tell your doctor or pharmacist if you notice any of the following side effects: Common (may affect up to 1 in 10 people)</p><p>thrush in the mouth (a fungal infection). Rinsing your mouth out with water immediately after using Riltrava Aerosphere may help prevent this.</p><p>feeling anxious</p><p>difficulty sleeping</p><p>feeling sick (nausea)</p><p>headache</p><p>coughing or a hoarse voice</p><p>muscle cramps</p><p>awareness of your heart beating (palpitations)</p><p>high blood sugar levels (as shown in tests)</p><p>painful and frequent urination (may be signs of a urinary tract infection)</p><p>pneumonia (infection of the lung). Tell your doctor if you have any of the following while using Riltrava Aerosphere, they could be symptoms of a lung infection:</p><p>fever or chills,</p><p>increased mucus production, change in mucus colour,</p><p>increased cough or increased breathing difficulties. Uncommon (may affect up to 1 in 100 people)</p><p>shaking, tremor or feeling dizzy</p><p>dry mouth, or mild irritation in the throat</p><p>bruising of the skin</p><p>feeling restless, nervous or agitated</p><p>depression</p><p>fast heart beat or uneven heart beat</p><p>chest pain or tightening in the chest (angina pectoris) Very rare (may affect up to 1 in 10,000 people)</p><p>changes in behaviour</p><p>an effect on the adrenal gland Not known (frequency cannot be estimated from the available data):</p><p>blurred vision</p><p>clouding of the lens of your eyes (signs of cataract)</p><p>increased pressure in the eye (glaucoma)</p><p>swelling of your face, particularly around your mouth (swelling of your tongue or throat may make it difficult to swallow) Reporting of side effects If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.</p></div>
</text>
</section>
<section>
<title value="5. How to store riltrava"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="5. How to store riltrava"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Keep this medicine out of the sight and reach of children. Do not use Riltrava Aerosphere after the expiry date which is stated on the carton, pouch and pressurised container after EXP . The expiry date refers to the last day of that month. After opening the pouch, the inhaler must be used within 3 months. Keep the inhaler inside the sealed pouch only remove the inhaler from the sealed pouch immediately before first use. On the day the pouch is opened, write the date on the inhaler label in the space provided. Do not store above 30 C. Store in a dry place. For best results, the inhaler should be at room temperature before you use it. Do not break, puncture or burn the pressurised container, even when apparently empty. Do not use or store near heat or open flames. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p></div>
</text>
</section>
<section>
<title value="6. Contents of the pack and other information"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="6. Contents of the pack and other information"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>What Riltrava Aerosphere contains The active substances are formoterol fumarate dihydrate, glycopyrronium and budesonide. Each single inhalation provides a delivered dose (the dose leaving the mouthpiece) of 5 micrograms of formoterol fumarate dihydrate, 9 micrograms glycopyrronium bromide equivalent to 7.2 micrograms glycopyrronium and 160 micrograms of budesonide. The other ingredients are norflurane, 1,2- distearoyl-sn-glycero-3-phosphocholine and calcium chloride. What Riltrava Aerosphere looks like and contents of the pack Riltrava Aerosphere is a pressurised inhalation, suspension. Riltrava Aerosphere comes as a canister with a dose indicator, supplied with a yellow plastic actuator body and white mouthpiece. The mouthpiece is covered with a removable grey protective cap. Riltrava Aerosphere is supplied in a foil pouch that contains a drying packing (desiccant) and packed into a carton. Each inhaler contains 120 puffs. Additionally, there are multipacks containing 3 pressurised containers with 120 puffs, each. Marketing Authorisation Holder AstraZeneca AB SE-151 85 S dert lje Sweden Manufacturer AstraZeneca Dunkerque Production 224 Avenue de la Dordogne Dunkerque 59France For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder: Belgi /Belgique/Belgien AstraZeneca S.A./N.V. Tel: +32 2 370 48 Lietuva UAB AstraZeneca Lietuva Tel: +370 5 2660</p><p>.: +359 24455Luxembourg/Luxemburg AstraZeneca S.A./N.V. T l/Tel: +32 2 370 48 esk republika AstraZeneca Czech Republic s.r.o. Tel: +420 222 807 Magyarorsz g AstraZeneca Kft. Tel.: +36 1 883 6Danmark AstraZeneca A/S Tlf: +45 43 66 64 Malta Associated Drug Co. Ltd Tel: +356 2277 8Deutschland AstraZeneca GmbH Tel: +49 40 809034Nederland AstraZeneca BV Tel: +31 85 808 9Eesti AstraZeneca Tel: +372 6549 Norge AstraZeneca AS Tlf: +47 21 00 64<br/>AstraZeneca A.E. : +30 210 6871 sterreich AstraZeneca sterreich GmbH Tel: +43 1 711 31 0 Espa a AstraZeneca Farmac utica Spain, S.A. Tel: +34 91 301 91 Polska AstraZeneca Pharma Poland Sp. z o.o. Tel.: +48 22 245 73 France AstraZeneca T l: +33 1 41 29 40 Portugal Tecnimede - Sociedade T cnico-Medicinal, S.A. Tel: +351 21 041 41 Hrvatska AstraZeneca d.o.o. Tel: +385 1 4628 Rom nia AstraZeneca Pharma SRL Tel: +40 21 317 60 Ireland AstraZeneca Pharmaceuticals (Ireland) DAC Tel: +353 1609 7Slovenija AstraZeneca UK Limited Tel: +386 1 51 35 sland Vistor hf. S mi: +354 535 7Slovensk republika AstraZeneca AB, o.z. Tel: +421 2 5737 7Italia AstraZeneca S.p.A. Tel: +39 02 00704Suomi/Finland AstraZeneca Oy Puh/Tel: +358 10 23</p><p>: +357 22490Sverige AstraZeneca AB Tel: +46 8 553 26 Latvija SIA AstraZeneca Latvija Tel: +371 67377United Kingdom (Northern Ireland) AstraZeneca UK Ltd Tel: +44 1582 836 This leaflet was last revised in Detailed information on this medicine is available on the European Medicines Agency web site:</p></div>
</text>
</section>
</section>
</Composition>
</resource>
</entry>
<entry>
<fullUrl
value="MedicinalProductDefinition/mp832482791de362ad81d3371194ed350b"/>
<resource>
<MedicinalProductDefinition>
<id value="mp832482791de362ad81d3371194ed350b"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/MedicinalProductDefinition-uv-epi"/>
</meta>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><a name="MedicinalProductDefinition_mp832482791de362ad81d3371194ed350b"> </a><p class="res-header-id"><b>Generated Narrative: MedicinalProductDefinition mp832482791de362ad81d3371194ed350b</b></p><a name="mp832482791de362ad81d3371194ed350b"> </a><a name="hcmp832482791de362ad81d3371194ed350b"> </a><a name="mp832482791de362ad81d3371194ed350b-en-US"> </a><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/21/1604/001 120 actuations</p><p><b>type</b>: <span title="Codes:{http://hl7.org/fhir/medicinal-product-type MedicinalProduct}">Medicinal Product</span></p><p><b>domain</b>: <span title="Codes:{http://hl7.org/fhir/medicinal-product-domain Human}">Human use</span></p><p><b>status</b>: <span title="Codes:{http://hl7.org/fhir/publication-status active}">active</span></p><p><b>legalStatusOfSupply</b>: <span title="Codes:{https://spor.ema.europa.eu/rmswi 100000072084}">Medicinal product subject to medical prescription</span></p><blockquote><p><b>name</b></p><p><b>productName</b>: Riltrava Aerosphere 5 micrograms/7.2 micrograms/160 micrograms pressurised inhalation,</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000001}">Full name</span></p><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000002}">Invented name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000003}">Scientific name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000004}">Strength part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000005}">Pharmaceutical dose form part</span></p></blockquote><h3>Usages</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Country</b></td><td><b>Jurisdiction</b></td><td><b>Language</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{urn:iso:std:iso:3166 EU}">EU</span></td><td><span title="Codes:{urn:iso:std:iso:3166 EU}">EU</span></td><td><span title="Codes:{urn:ietf:bcp:47 en}">en</span></td></tr></table></blockquote></div>
</text>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="EU/1/21/1604/001 120 actuations"/>
</identifier>
<type>
<coding>
<system value="http://hl7.org/fhir/medicinal-product-type"/>
<code value="MedicinalProduct"/>
<display value="Medicinal Product"/>
</coding>
</type>
<domain>
<coding>
<system value="http://hl7.org/fhir/medicinal-product-domain"/>
<code value="Human"/>
<display value="Human use"/>
</coding>
</domain>
<status>
<coding>
<system value="http://hl7.org/fhir/publication-status"/>
<code value="active"/>
<display value="active"/>
</coding>
</status>
<legalStatusOfSupply>
<coding>
<system value="https://spor.ema.europa.eu/rmswi"/>
<code value="100000072084"/>
<display
value="Medicinal product subject to medical prescription"/>
</coding>
</legalStatusOfSupply>
<name>
<productName
value="Riltrava Aerosphere 5 micrograms/7.2 micrograms/160 micrograms pressurised inhalation,"/>
<type>
<coding>
<system value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000001"/>
<display value="Full name"/>
</coding>
</type>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000002"/>
<display value="Invented name part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000003"/>
<display value="Scientific name part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000004"/>
<display value="Strength part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000005"/>
<display value="Pharmaceutical dose form part"/>
</coding>
</type>
</part>
<usage>
<country>
<coding>
<system value="urn:iso:std:iso:3166"/>
<code value="EU"/>
<display value="EU"/>
</coding>
</country>
<jurisdiction>
<coding>
<system value="urn:iso:std:iso:3166"/>
<code value="EU"/>
<display value="EU"/>
</coding>
</jurisdiction>
<language>
<coding>
<system value="urn:ietf:bcp:47"/>
<code value="en"/>
<display value="en"/>
</coding>
</language>
</usage>
</name>
</MedicinalProductDefinition>
</resource>
</entry>
</Bundle>
IG © 2021+ Gravitate Health Project. Package hl7.eu.fhir.ghepi#0.1.0 based on FHIR 5.0.0. Generated 2024-10-14
Links: Table of Contents |
QA Report
The Gravitate Health project has received funding from the IMI 2 Joint Undertaking under grant agreement No 945334.
This joint undertaking receives support from the EU H2020 research and innovation programme and EFPIA.
